Skip to main content
. 2012 Jul 16;75(2):507–521. doi: 10.1111/j.1365-2125.2012.04381.x

Table 4.

Incidence of all grade ≥3 treatment-related AEs that occurred during the study

Term CTCAE grade Number of patients (%)
Eribulin only (n = 14) Total (n = 14)
Any TEAE 3 6 (43) 8 (57)
4 1 (7.1) 2 (14)
Fatigue 3 3 (21) 3 (21)
Leucopenia 3 4 (29) 3 (21)
4 0 1 (7.1)
Neutropenia 3 2 (14) 4 (29)
4 1 (7.1) 2 (14)
Febrile neutropenia 3 1 (7.1) 1 (7.1)
Abdominal pain 3 0 1 (7.1)

TEAE, treatment-emergent adverse event.